(Q44045735)

29 November 2017

title

The cellular pharmacology of oxaliplatin resistance (English)

1 reference

29 November 2017

1 reference

1 reference

Mishima M

1

1 reference

29 November 2017

Samimi G

2

1 reference

29 November 2017

Kondo A

3

1 reference

29 November 2017

Lin X

4

1 reference

29 November 2017

Howell SB

5

1 reference

29 November 2017

language of work or name

1 reference

1 July 2002

1 reference

European Journal of Cancer

29 November 2017

published in

1 reference

29 November 2017

volume

38

1 reference

29 November 2017

issue

10

1 reference

29 November 2017

page(s)

1405-1412

1 reference

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Oxaliplatin clinical activity: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Cellular accumulation of the anticancer agent cisplatin: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Overexpression of metallothionein confers resistance to anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Mechanism of translesion DNA synthesis by DNA polymerase II. Comparison to DNA polymerases I and III core

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

The ability of a variety of polymerases to synthesize past site-specific cis-syn, trans-syn-II, (6-4), and Dewar photoproducts of thymidylyl-(3'-->5')-thymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

DNA polymerase mutagenic bypass and proofreading of endogenous DNA lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

DNA repair, DNA replication, and UV mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900096-5

7 January 2021

10.1016/S0959-8049(02)00096-5

Identifiers

DOI

1 reference

29 November 2017

1 reference